Navigation Links
Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
Date:12/5/2007

Australian Quarantine & Inspection Service approves permit for NKO(R)

import

LAVAL, QC, Dec. 5 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has received notification from the Therapeutic Goods Administration (TGA) in Australia that Neptune Krill Oil (NKO(R)) has obtained approval as a complementary medicine allowing immediate commercialization in Australia hence New Zealand, which automatically allows TGA approved products.

The Department of Health and Aging of the TGA has accepted and registered, in the Australian Register of Therapeutic Goods, Neptune Krill Oil under the Australian Approved Biological Name "Euphausia superba oil". In addition, the Australian Quarantine and Inspection Service has granted a permit to import quarantine material of NKO(R).

"In Australia and New Zealand complementary medicines are classified as a subset of over-the-counter (OTC) pharmaceuticals," stated Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Considering the very tight regulatory control by the TGA, obtaining complementary medicine approval and the quarantine permit constitute a major breakthrough for Neptune in Australia and New Zealand," she added.

"Physician and other healthcare practitioner recommendations have always had a positive impact on our sales. Bearing in mind that 50% of complementary medicines in Australia are sold through medical recommendations and in pharmacies(1), we are seeking a strategic alliance with a major local partner in order to commercialize NKO(R) in these targeted markets. In order to support penetration in this new market, Neptune expects to be actively participating in the near future with such a partner in a series of medical conventions, seminars and media conferences to introduce the scientific data, clinical research and health benefits of NKO(R) to physicians and other healthcare practitioners as well as the end consumer," added Dr. Sampalis.

1. Source: Australian Self-Medication Industry (ASMI)

http://www.asmi.com.au/Complementary%20Medicine.htm

About Neptune Technologies & Bioressources Inc.

Neptune develops proprietary health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, the Company is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neptune continues to actively pursue its strategic development plan to form partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. Neptune has recently signed agreements with Nestle and Yoplait, worldwide leading food manufacturers, paving its entrance into the global functional food market. According to its business strategy, negotiations are ongoing with pharmaceutical companies with the objective of entering the pharmaceutical market by licensing rights.

NASDAQ and TSX venture exchange does not accept responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
9. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
10. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
11. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... regenerative medicine, has announced a new agreement with Singapore-based Global Stem Cells Network ... from the Philippines, Thailand and Singapore in the latest adipose and bone marrow ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... current winner of the Highest Overall Customer Rating Award from Circuits Assembly , ... business units across the USA, Canada, Mexico and China. , The EMS provider, ...
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Regenicin, ... biotechnology company specializing in the development and commercialization ... of damaged tissues and organs, recently reported the ... the first quarter of 2016. Lonza ... the new 2015 fiscal year in the process ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):